CASI Pharmaceuticals Inc.: Received MNPA (f.k.a. CFDA) approval for EVOMELA® (melphalan for injection: multiple myeloma) on Dec 3, 2018; CFDA review in progress for ZEVALIN® and MARQIBO® (in-licensed from Spectrum Pharma). Acqd 25 US FDA-approved ANDAS from Sandoz in Jan 2018.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Disease Space
Oncology
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Address:
9620 Medical Center Drive
Suite 300
Rockville, MD 20850
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.